These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 23258593)

  • 1. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury.
    Chen M; Borlak J; Tong W
    Hepatology; 2013 Jul; 58(1):388-96. PubMed ID: 23258593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations of Drug Lipophilicity and Extent of Metabolism with Drug-Induced Liver Injury.
    McEuen K; Borlak J; Tong W; Chen M
    Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28640208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals.
    Lammert C; Einarsson S; Saha C; Niklasson A; Bjornsson E; Chalasani N
    Hepatology; 2008 Jun; 47(6):2003-9. PubMed ID: 18454504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive study of the association between drug hepatotoxicity and daily dose, liver metabolism, and lipophilicity using 975 oral medications.
    Weng Z; Wang K; Li H; Shi Q
    Oncotarget; 2015 Jul; 6(19):17031-8. PubMed ID: 26220713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A testing strategy to predict risk for drug-induced liver injury in humans using high-content screen assays and the 'rule-of-two' model.
    Chen M; Tung CW; Shi Q; Guo L; Shi L; Fang H; Borlak J; Tong W
    Arch Toxicol; 2014 Jul; 88(7):1439-49. PubMed ID: 24958025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA-approved drug labeling for the study of drug-induced liver injury.
    Chen M; Vijay V; Shi Q; Liu Z; Fang H; Tong W
    Drug Discov Today; 2011 Aug; 16(15-16):697-703. PubMed ID: 21624500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative structure-activity relationship models for predicting drug-induced liver injury based on FDA-approved drug labeling annotation and using a large collection of drugs.
    Chen M; Hong H; Fang H; Kelly R; Zhou G; Borlak J; Tong W
    Toxicol Sci; 2013 Nov; 136(1):242-9. PubMed ID: 23997115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Model to predict severity of drug-induced liver injury in humans.
    Chen M; Borlak J; Tong W
    Hepatology; 2016 Sep; 64(3):931-40. PubMed ID: 27302180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety data and withdrawal of hepatotoxic drugs.
    Babai S; Auclert L; Le-Louët H
    Therapie; 2021; 76(6):715-723. PubMed ID: 29609830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Vitro Drug-Induced Liver Injury Prediction: Criteria Optimization of Efflux Transporter IC50 and Physicochemical Properties.
    Yucha RW; He K; Shi Q; Cai L; Nakashita Y; Xia CQ; Liao M
    Toxicol Sci; 2017 Jun; 157(2):487-499. PubMed ID: 28369588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system.
    Raschi E; Poluzzi E; Koci A; Salvo F; Pariente A; Biselli M; Moretti U; Moore N; De Ponti F
    Br J Clin Pharmacol; 2015 Aug; 80(2):285-93. PubMed ID: 25689417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A high content screening assay to predict human drug-induced liver injury during drug discovery.
    Persson M; Løye AF; Mow T; Hornberg JJ
    J Pharmacol Toxicol Methods; 2013; 68(3):302-13. PubMed ID: 23933113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatotoxicity by Drugs: The Most Common Implicated Agents.
    Björnsson ES
    Int J Mol Sci; 2016 Feb; 17(2):224. PubMed ID: 26861310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-induced liver injury: what was new in 2013?
    Chalhoub WM; Sliman KD; Arumuganathan M; Lewis JH
    Expert Opin Drug Metab Toxicol; 2014 Jul; 10(7):959-80. PubMed ID: 24746272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a Battery of
    Rathman J; Yang C; Ribeiro JV; Mostrag A; Thakkar S; Tong W; Hobocienski B; Sacher O; Magdziarz T; Bienfait B
    Chem Res Toxicol; 2021 Feb; 34(2):601-615. PubMed ID: 33356149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work.
    Suzuki A; Andrade RJ; Bjornsson E; Lucena MI; Lee WM; Yuen NA; Hunt CM; Freston JW
    Drug Saf; 2010 Jun; 33(6):503-22. PubMed ID: 20486732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Physicochemical Properties on Dose and Hepatotoxicity of Oral Drugs.
    Leeson PD
    Chem Res Toxicol; 2018 Jun; 31(6):494-505. PubMed ID: 29722540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Sakatis MZ; Reese MJ; Harrell AW; Taylor MA; Baines IA; Chen L; Bloomer JC; Yang EY; Ellens HM; Ambroso JL; Lovatt CA; Ayrton AD; Clarke SE
    Chem Res Toxicol; 2012 Oct; 25(10):2067-82. PubMed ID: 22931300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events.
    Lammert C; Bjornsson E; Niklasson A; Chalasani N
    Hepatology; 2010 Feb; 51(2):615-20. PubMed ID: 19839004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury.
    Yu K; Geng X; Chen M; Zhang J; Wang B; Ilic K; Tong W
    Drug Metab Dispos; 2014 Apr; 42(4):744-50. PubMed ID: 24464804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.